Depo-Provera Settlement Information to Be Presented Through Town Hall Meeting

Court indicates Depo-Provera lawsuit payouts for qualifying women with meningioma brain tumors could begin as early as 2027.

Attorneys have finished hammering out the details of a Master Settlement Agreement (MSA) that seeks to resolve thousands of pending Depo-Provera meningioma lawsuits brought by women who say the popular birth control shot caused them to develop debilitating brain tumors. However, information about the Depo-Provera settlement will not be presented until a town hall meeting is scheduled.

Depo-Provera is a long-acting birth control injection that has been available since the 1990s and used by tens of millions of women. It contains medroxyprogesterone acetate, a synthetic form of progesterone that provides contraceptive protection for about three months after each injection.

The litigation emerged after a study was published in 2024, indicating that Depo-Provera increased a woman’s risk of an intracranial meningioma by a factor of five. These brain tumors develop in the membranes surrounding the brain and spinal cord. Although usually non-cancerous, they can still grow large enough to cause serious complications as they press on parts of the brain and nerves. Treatment often requires intricate and complex brain surgery, life-long medical monitoring or both.

According to recent court documents, nearly 6,300 Depo-Provera brain tumor lawsuits filed in the federal court system may be eligible to participate in a global settlement agreement intended to resolve the litigation.

Depo-Provera Settlement Agreement

Due to common questions of fact and law, the claims have been consolidated as part of a multidistrict litigation (MDL) in the Northern District of Florida, where U.S. District Judge M. Casey Rodgers has been presiding over coordinated discovery and pretrial proceedings.

Counsel for plaintiffs and Pfizer first announced a tentative Depo-Provera settlement agreement in June 2026. However, details of the settlement have not yet been publicly released, leaving potential claimants uncertain of the eligibility requirements, potential payout amounts and how individual claims will be evaluated.

On July 27, Judge Rodgers held a case management conference with lead attorneys for the plaintiffs and defendants. New York Justice Sabrina Kraus, who is overseeing 132 related state court claims, and Delaware Judge Kathleen Vavala, whose court is handling another 337 cases, also participated.

A joint status report (PDF) issued on July 27 noted that there are also 118 claims in California state court, 13 cases in Connecticut representing 76 plaintiffs, 72 lawsuits in Minnesota state court that represent 6,899 plaintiffs, 12 claims in Illinois, two in New Mexico and one each in New Hampshire, Washington state and Wisconsin.

According to a case management order (PDF) issued by Judge Rodgers that same day, the Court was briefed on the details of the Depo-Provera settlement agreement, including eligibility requirements, but noted that the settlement involves a confidentiality agreement preventing that information from being released to the public.

The order notes that the detailed Depo-Provera settlement information will be presented to plaintiffs at an upcoming town hall meeting. However, the order does not contain a scheduled date for that meeting.

“The Parties represent that Settlement registration should be completed in November 2026, with the claims process beginning to be completed and payments beginning to roll out by the first quarter of 2027.”

– U.S. District Judge M. Casey Rodgers, Northern District of Florida

Judge Rodgers indicated plaintiffs defined as eligible in the MSA will not have their eligibility affected by any future court rulings. However, Pfizer has filed a motion for summary judgment claiming that plaintiffs cannot prove Depo-Provera use caused patients’ brain tumors.

Regardless of the outcome of that order, everyone who currently qualifies will still be allowed to participate in the settlement, the judge explained.

Plans for Depo-Provera “Pilot” Trials Proceed

Early in the litigation, Judge Rodgers ordered attorneys to prepare five “pilot” lawsuits for bellwether trials. These early test cases are designed to give plaintiffs and defendants an opportunity to see how juries respond to evidence and testimony that would be repeated in thousands of claims if they were to go to trial.

However, the order indicates that the plaintiffs in all five lawsuits are eligible for the settlement agreement. According to the judge and counsel for both sides, the trials should move forward, but with different cases chosen from the remaining claims involving circumstances that make the plaintiffs ineligible for the settlement terms.

Counsel and the judge agreed to select claims filed by Christina Yeager, Vivian Davis and Katherine Allison Ponder to serve as the new pilot cases.

If the remaining claims cannot be resolved through the settlement or following the bellwether trials, Judge Rodgers may remand any remaining complaints back to the federal District where they originated for individual trial dates.

The next case management conference is scheduled for September 18, 2026. Judge Rodgers has requested a Joint Agenda Letter be submitted by September 14 to the MDL court, as well as to the courts of New York, Delaware and California.

To stay up to date with this litigation, sign up to receive Depo-Provera lawsuit updates sent directly to your inbox.